API
< Back to all clusters
[TECHNOLOGY] · United States · 2 sources

started · updated

Boltz raises $110 million for medical AI drug discovery

Boltz PBC, a medical AI startup, has secured $110 million in Series A funding to accelerate small molecule research. The investment round was led by Bessemer Venture Partners, with participation from several new and returning investors, including Andreessen Horowitz, Amplify Partners, Greycroft, F-Prime Capital, and Hummingbird.

The company develops artificial intelligence models, such as BoltzMol-1, designed to assist pharmaceutical researchers in biomolecular modeling and protein design. The technology aims to streamline the drug discovery process by generating binding affinity data. Instead of reviewing hundreds of thousands of candidate molecules, which is a costly and time-consuming process, the AI model can identify promising small molecule hits by evaluating only a few dozen candidates.

In testing, Boltz staffers utilized the model to search for hits across ten therapeutically relevant targets, successfully identifying hits for six of them. The model can be customized to specific research constraints, such as limited compound availability.

Entities

Andreessen Horowitz · Bessemer Venture Partners · Boltz PBC · BoltzMol-1 · Latham & Watkins